Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Strongbridge Dublin
Dublin, Irelandstrongbridgebio.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Other
01
Overview
Strongbridge Biopharma was a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare endocrine and neuromuscular diseases. The company's portfolio included Recorlev (levoketoconazole) for the treatment of endogenous Cushing's syndrome and Keveyis (dichlorphenamide) for primary periodic paralysis. Strongbridge was headquartered in Dublin, Ireland, and maintained a significant presence in the United States. In October 2021, the company was acquired by Xeris Biopharma Holdings, creating a diversified rare disease company.
- Therapeutic areas
- NeurologyEndocrinology
- Modalities
- Small moleculePeptides
- Industry
- Biotech
02
Partnerships
Novo NordiskAntisense Therapeutics
Beyond the preview
Go deeper on Strongbridge Dublin.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Strongbridge Dublin.